Results 161 to 170 of about 9,316,170 (262)

Should Age 65 be a cutoff for Primary Progressive Multiple Sclerosis therapy? Real World Data is Critical. [PDF]

Neurotherapeutics, 2023
Coyle PK.
europepmc   +1 more source

Aortic valve disease: Novel animal models for advancing our understanding of the underlying mechanisms

Animal Models and Experimental Medicine, EarlyView.
Due to the complex pathophysiology of aortic valve disease (AVD) and the resulting lack of effective pharmacotherapy, existing animal models are valuable research tools, but each has its own strengths and limitations. This review systematically surveys the major AVD models, compares their induction methods, pathological features, advantages and ...
Liya Hou, Xue Liu, Wangxing Hu, Xianbao Liu, Wei Zhu   +4 more
wiley   +1 more source

Primary Progressive Multiple Sclerosis With Acute Neurologic Deterioration Secondary to Metabolic Derangements and Medication Effects. [PDF]

Cureus
Boddakayala V, Mirnateghi A, Nakov KM, Pattathan M.   +3 more
europepmc   +1 more source

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY). [PDF]

Neurotherapeutics, 2023
Chisari CG, Bianco A, Brescia Morra V, Calabrese M, Capone F, Cavalla P, Chiavazza C, Comi C, Danni M, Filippi M, Iaffaldano P, Lanzillo R, Lo Fermo S, Lucisano A, Lugaresi A, Lus G, Marfia GA, Marinelli F, Mirabella M, Moiola L, Perin C, Realmuto S, Toscano S, Trojano M, Vecchio D, Patti F, Italian MS Registry.   +26 more
europepmc   +1 more source

Toward a Behavioral Reserve Model in Amyotrophic Lateral Sclerosis

Annals of Neurology, EarlyView.
Objective Behavioral impairment is common in amyotrophic lateral sclerosis (ALS) and strongly affects autonomy, caregiver burden, and outcomes, yet predictors of vulnerability remain unclear. We investigated whether premorbid regulatory traits and socio‐educational exposures are associated with behavioral phenotypes in ALS within a behavioral reserve ...
Francesca Palumbo, Barbara Iazzolino, Cristina Moglia, Umberto Manera, Enrico Matteoni, Sara Cabras, Giorgio Pellegrino, Emilio Minerva, Vita Passidomo, Rosario Vasta, Gabriele Mora, Fabrizio D’Ovidio, Antonio Canosa, Andrea Calvo, Adriano Chiò   +14 more
wiley   +1 more source

Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab. [PDF]

Mult Scler
MacMillan EL, Russell-Schulz B, Alejo G, Harp C, Cameron B, Winger R, Jia S, Herman A, Kassam J, Waine M, Vavasour IM, Cross H, Tam R, Traboulsee AL, Carruthers R, Kolind SH.   +15 more
europepmc   +1 more source

The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry. [PDF]

BMC Neurol, 2023
Braune S, Bluemich S, Bruns C, Dirks P, Hoffmann J, Heer Y, Rouzic EM, Bergmann A, NTD Study Group.   +8 more
europepmc   +1 more source

Neurotransmitter‐Defined Degeneration Patterns in Sporadic and C9orf72‐Associated Amyotrophic Lateral Sclerosis: Predilection to GABAergic, Serotonergic, Opioid, Glutamatergic, Endocannabinoid, and Microglial Systems—Implications for Therapy Development

Annals of Neurology, EarlyView.
Objective Amyotrophic lateral sclerosis (ALS) has a markedly distinctive clinical and neuroradiological signature, with the preferential involvement of specific brain networks and the apparent sparing of others. The molecular underpinnings of the strikingly selective anatomical vulnerability have not been fully elucidated to date despite the potential ...
Marlene Tahedl, We Fong Siah, Jasmin Lope, Jennifer C. Hengeveld, Mark A. Doherty, Russell L. McLaughlin, Orla Hardiman, Ee Ling Tan, Alison Toomey, Jana Kleinerova, Peter Bede   +10 more
wiley   +1 more source

Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis. [PDF]

Eur J Neurol
Fissolo N, Benkert P, Vilaseca-Jolonch A, Blanco Y, Hegen H, Berek K, Pérez-Miralles F, Rejdak K, Villar L, Monreal E, Alvarez-Lafuente R, Bachhuber F, Tumani H, Martínez-Yelamos S, Sánchez-López A, García-Merino A, Gutiérrez L, Castillo-Triviño T, Lycke J, Rosenstein I, Téllez N, Furlan R, Lünemann JD, Khalil M, Kuhle J, Montalban X, Comabella M.   +26 more
europepmc   +1 more source

Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis. [PDF]

Int J Mol Sci, 2023
Gernert JA, Böhm L, Starck M, Buchka S, Kümpfel T, Kleiter I, Havla J.   +6 more
europepmc   +1 more source